Human Influenza A/PR/8/34 (H1N1) Purified Virus

Catalog #: 10-210-500

Size: 0.5 mg

In Stock

Biological Substance B

This material requires a signed and fully executed Advanced Biotechnologies Inc agreement with possible fees, prior to purchase. To begin this process, please complete the Intended Use form and return it to agreements@abionline.com.

Intended Use Form

DETAILS RESOURCES RELATED PRODUCTS

Human Influenza A/PR/8/34 (H1N1) virus purified from infected chicken embryo allantoic fluid.

≥ 5 x 10¹⁰ viral particles per mL of purified Human Influenza A/PR/8/34 (H1N1)

≥ 10^8.0 TCID₅₀ per mL of purified Human Influenza A/PR/8/34 (H1N1)

For research use only.

APPLICATION FOR USE

In vitro Infectivity Assay
Hemagglutination Assay (HA)
Antiviral Studies
Animal Experimentation
Nucleic Acid Extraction
Spiking Studies
Hemagglutination Inhibition Assay (HAI)
Virus Neutralization Assay
Virus Ultrastructural Studies

QUALITY CONTROL TESTING INCLUDES

Sterility
TCID50
Hemagglutination Assay
Protein Concentration
Virus Particle Count

SHIPPING AND STORAGE:

This product is shipped frozen on dry ice. Store at -70°C upon receipt. Avoid multiple freeze-thaw cycles as product degradation may result.

RECOMMENDATIONS:

Upon thawing, centrifuge the vial for a few seconds to remove residual droplets from the lid.

SAFE HANDLING RECOMMENDATIONS:

This preparation of Influenza virus is a BIOHAZARDOUS material containing ACTIVE VIRUS and should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. (CDC) 21-1112.

DOCUMENTATION

Certificate of Analysis

Safety Data Sheet

300-10-210-500

REFERENCE ARTICLES

Roosenhoff, R., Reed, V., Kenwright, A., Schutten, M., Boucher, C., Monto, A., Clinch, B., Kumar, D., Whitley, R., and Nguyen-Van-Tam, J. et al. (2019). Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, ciz939. https://doi.org/10.1093/cid/ciz939

Roosenhoff, R., van der Vries, E., van der Linden, A., van Amerongen, G., Stittelaar, K., Smits, S., Schutten, M., and Fouchier, R. (2018). Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance. PLOS ONE 13, e0200849. https://doi.org/10.1371/journal.pone.0200849

Barauskas, O., Xing, W., Aguayo, E., Willkom, M., Sapre, A., Clarke, M., Birkus, G., Schultz, B., Sakowicz, R., and Kwon, H. et al. (2017). Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs. PLOS ONE 12, e0185998. https://doi.org/10.1371/journal.pone.0185998

Jaligama, S., Saravia, J., You, D., Yadav, N., Lee, G., Shrestha, B., and Cormier, S. (2017). Regulatory T cells and IL10 suppress pulmonary host defense during early-life exposure to radical containing combustion derived ultrafine particulate matter. Respiratory Research 18:15. https://doi.org/10.1186/s12931-016-0487-4

Naikawadi, R., Disayabutr, S., Mallavia, B., Donne, M., Green, G., La, J., Rock, J., Looney, M., and Wolters, P. (2016). Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. JCI Insight 1, e86704. https://doi.org/10.1172/jci.insight.86704

Lee, G., Saravia, J., You, D., Shrestha, B., Jaligama, S., Hebert, V., Dugas, T., and Cormier, S. (2014). Exposure to combustion generated environmentally persistent free radicals enhances severity of influenza virus infection. Particle And Fibre Toxicology 11:57. https://doi.org/10.1186/s12989-014-0057-1

CATALOG #

PRODUCT NAME

SIZE

PRICE

PRODUCTS